📋 Key Information Summary
- Refeeding syndrome (RFS) is a potentially fatal condition caused by rapid reintroduction of nutrition after prolonged starvation, leading to acute shifts in electrolytes — primarily phosphate, potassium and magnesium — into depleted cells.
- Key electrolyte derangement is severe hypophosphataemia (<0.5 mmol/L), which can trigger cardiac failure, respiratory failure, rhabdomyolysis, seizures and death within days.
- Highest-risk patients: BMI <16 kg/m², >15% unintentional weight loss over 3–6 months, little or no nutritional intake for >10 days, and pre-feeding phosphate, potassium or magnesium below the normal range.
- Additional high-risk groups: chronic alcohol use disorder, anorexia nervosa, prolonged fasting (>5 days), active malignancy, post-bariatric surgery, chronic malabsorption and chronic use of antacids or diuretics.
- Thiamine replacement (200–300 mg IV or PO) and vitamin B complex must be given at least 30 minutes before — and for the first 3 days of — any refeeding.
- Start nutrition cautiously: 5–10 kcal/kg/day in highest-risk patients and 10–15 kcal/kg/day in high-risk patients; do not exceed 10 kcal/kg/day on day 1 for the very highest risk.
- Titrate caloric intake by no more than 5 kcal/kg/day every 2–3 days towards goal, ensuring electrolytes remain within normal limits before each increase.
- Mandatory daily monitoring of phosphate, magnesium, potassium, calcium, sodium and glucose for the first 72 hours; pre-feed ECG and continuous telemetry for highest-risk patients.
- Prophylactic daily electrolyte replacement is essential: phosphate 0.3–0.6 mmol/kg/day, magnesium 0.2 mmol/kg/day, potassium 1–2 mmol/kg/day — starting from day 1 of refeeding.
- Use cautious fluid management (restrict to 15–20 mL/kg/day); refeeding-associated fluid retention can precipitate acute heart failure and pulmonary oedema.
- Multidisciplinary team involvement is mandatory — dietitian, physician, pharmacist, nursing, and mental health support (especially in anorexia nervosa or chronic alcohol use disorder).
- Aboriginal and Torres Strait Islander peoples are disproportionately affected by food insecurity, chronic disease and malnutrition; culturally safe refeeding pathways must be integrated with local Aboriginal Medical Services.
Introduction & Australian Epidemiology
Refeeding syndrome (RFS) describes the potentially fatal metabolic derangement that occurs when nutrition — oral, enteral or parenteral — is reintroduced to a patient who has been chronically or severely malnourished. The hallmark is rapid intracellular movement of phosphate, potassium and magnesium driven by insulin release and anabolic recovery, causing life-threatening serum depletions.
First described among famine victims after World War II, RFS remains a common and under-recognised complication in contemporary Australian hospitals. The AIHW reports that malnutrition affects 20–50% of Australian hospital inpatients, and a significant proportion of those requiring nutritional rehabilitation are at risk of RFS. The condition carries a reported mortality of up to 25% when severe hypophosphataemia is not promptly recognised and treated.
In Australia, high-risk populations include patients with anorexia nervosa (estimated prevalence 1–2% in young women, per Butterfly Foundation data), chronic alcohol use disorder — particularly prevalent in remote and Indigenous communities — advanced malignancy, chronic bowel disease, post-bariatric surgery patients, and elderly individuals in residential aged-care facilities. NHMRC-endorsed screening tools such as the Malnutrition Screening Tool (MST) should be used at every hospital admission and aged-care review.
This guideline synthesises current NICE CG32, ASPEN 2020 clinical guidance, and Australasian Society of Parenteral and Enteral Nutrition (AuSPEN) recommendations for risk stratification, prevention and management of refeeding syndrome.
Pathophysiology
During prolonged starvation (typically >48–72 hours), the body adapts by shifting from glucose-based to fat and ketone-based metabolism. Intracellular stores of phosphate, potassium and magnesium become progressively depleted, although serum levels may remain low-normal due to extracellular redistribution and reduced renal excretion. This gives a misleading impression of metabolic stability.
When carbohydrate-rich nutrition is reintroduced, insulin secretion rises sharply. Insulin stimulates the sodium–potassium ATPase pump (Na⁺/K⁺-ATPase), driving phosphate, potassium, magnesium, glucose and water into cells. Simultaneously, anabolic processes (protein synthesis, glycolysis, ATP production) consume intracellular phosphate and magnesium at accelerated rates. The result is a rapid, often precipitous drop in serum phosphate, potassium and magnesium within 12–72 hours of refeeding onset.
The consequences are multi-organ:
- Cardiac: Hypophosphataemia impairs myocardial contractility (reduced ATP), leading to heart failure, arrhythmias and cardiac arrest. Thiamine deficiency compounds this with high-output heart failure (wet beriberi).
- Respiratory: Diaphragmatic muscle weakness from depleted ATP and phosphate reduces respiratory drive, potentially causing acute respiratory failure.
- Metabolic: Refeeding-induced hyperglycaemia and hyperinsulinaemia exacerbate intracellular fluid shift, causing fluid overload and oedema.
- Neurological: Hypophosphataemia can cause confusion, seizures, paraesthesias, and Wernicke encephalopathy (from concomitant thiamine depletion).
- Haematological: Reduced 2,3-DPG from low phosphate impairs oxygen delivery; haemolysis may occur at very low phosphate levels.
The severity of RFS correlates directly with the degree of pre-existing malnutrition and the rate of caloric reintroduction. This is why a graduated, protocol-driven approach to refeeding is essential.
Clinical Presentation & Diagnostic Criteria
There is no single universally accepted diagnostic criterion for RFS. The diagnosis is clinical, supported by laboratory findings, and is defined as the onset of electrolyte and fluid abnormalities following the initiation of nutrition in a malnourished patient. The NICE CG32 guideline (2006, updated 2017) and the Academy of Nutrition and Dietetics (AND) consensus definition require:
Diagnostic criteria (AND/NICE consensus): RFS is defined by the onset of ≥2 of the following abnormalities within 5 days of initiating or significantly increasing nutrition in a patient at risk: hypophosphataemia (<0.6 mmol/L or a decrease ≥0.16 mmol/L from baseline), hypokalaemia (<3.5 mmol/L), hypomagnesaemia (<0.7 mmol/L), or thiamine deficiency-related complications.
Timeline of onset:
0–12 hours
Asymptomatic electrolyte shifts; laboratory changes may precede symptoms. Thiamine deficiency complications (Wernicke encephalopathy) may manifest early.
12–72 hours
Peak risk period. Symptomatic hypophosphataemia (weakness, confusion, respiratory failure), cardiac arrhythmias, peripheral oedema, acute heart failure, seizures. Most RFS-related deaths occur in this window.
72 hours – 7 days
If electrolytes are actively monitored and replaced, the acute danger passes. Continuing oedema and fluid overload may persist. Delayed refeeding-associated liver dysfunction may emerge with parenteral nutrition.
Presenting features to recognise:
- New-onset or worsening peripheral or sacral oedema
- Tachycardia, new arrhythmias, or signs of acute heart failure (dyspnoea, raised JVP, pulmonary crepitations)
- Acute respiratory failure or unexplained hypoxaemia (diaphragmatic weakness)
- Generalised muscle weakness, including difficulty weaning from ventilator support
- Seizures, confusion, Wernicke encephalopathy (ophthalmoplegia, ataxia, confusion)
- Rhabdomyolysis (dark urine, elevated CK) at very low phosphate levels
- Hyperglycaemia, particularly in previously malnourished patients commenced on glucose-containing feeds
Risk Assessment
Screening for RFS risk must be performed before any nutrition support is initiated. NICE CG32 and ASPEN 2020 guidelines identify specific clinical criteria. Patients meeting one or more high-risk criteria or two or more other-risk criteria should be managed with a refeeding protocol.
Highest risk (NICE criteria — patient meets ONE or more): BMI <16 kg/m²; unintentional weight loss >15% over the preceding 3–6 months; little or no nutritional intake for >10 days; low baseline phosphate, potassium or magnesium before feeding commences.
High risk (patient meets TWO or more): BMI <18.5 kg/m²; unintentional weight loss >10% over the preceding 3–6 months; little or no nutritional intake for >5 days; history of alcohol misuse, chemotherapy, antacids, or diuretics.
High-Risk Groups in Australian Practice
| High-Risk Group | Mechanism of Risk | Australian Relevance |
|---|---|---|
| Anorexia nervosa | Prolonged self-imposed starvation, severe cachexia | ~1–2% prevalence in young women; butterfly foundation estimates ~1 million Australians affected by eating disorders |
| Chronic alcohol use disorder | Poor intake, vomiting, thiamine depletion, direct cardiac and hepatic toxicity | Significant burden in rural, remote and Indigenous communities; highest hospitalisation rates in NT and WA |
| Prolonged fasting (>5–10 days) | Complete substrate depletion; metabolic adaptation to ketosis | Post-operative patients (prolonged ileus, strict NBM), critically ill ICU patients |
| Active malignancy | Cancer cachexia, chemotherapy-induced anorexia and mucositis | Nutritional failure in ~30–50% of advanced cancer patients (Cancer Council Australia) |
| Post-bariatric surgery | Reduced absorptive surface, rapid food restriction, dumping | Rising prevalence with ~20,000 bariatric procedures annually in Australia |
| Chronic malabsorption | Coeliac disease, short bowel syndrome, IBD — chronic micronutrient loss | Coeliac prevalence ~1% nationally |
| Elderly / residential aged care | Sarcopenia, poor dentition, polypharmacy, social isolation | Malnutrition prevalence 22–50% in aged-care facilities (AIHW) |
Pre-Feeding Laboratory Assessment
Before commencing any nutrition support, obtain and review:
Essential
Serum phosphate
Low-normal range may mask severe intracellular depletion
Essential
Serum potassium
Target 3.5–5.0 mmol/L before feeding
Essential
Serum magnesium
Target 0.7–1.0 mmol/L; intracellular depletion common
Essential
Serum sodium, calcium, glucose
Baseline for fluid and metabolic monitoring
Essential
12-lead ECG
Baseline QTc, arrhythmia screen; repeat if electrolytes abnormal
Available
Thiamine (vitamin B1) level
If available; treat empirically in high-risk patients regardless
Available
Liver function tests, albumin, prealbumin
Nutritional status and hepatic reserve assessment (MBS 66512)
Available
CK, LDH, blood gas
Rhabdomyolysis screen if suspected; venous pH for metabolic assessment
Prevention & Management
Prevention is far more effective than treatment of established RFS. The following protocol should be applied to all patients identified as at risk by the screening criteria above. This protocol is adapted from NICE CG32, ASPEN 2020, AuSPEN guidelines and Australian clinical practice.
Step 1: Pre-Feeding Thiamine & Vitamin Supplementation
Critical safety alert: Thiamine MUST be administered at least 30 minutes before — and for a minimum of 3 days after — the commencement of any nutrition. Failure to replete thiamine first risks precipitating Wernicke encephalopathy, which may be irreversible.
Thiamine (Vitamin B1)
Parentrovite® IV · Bevit Forte® IV · Generic PO
Adult dose
200–300 mg IV or PO daily for ≥3 days; severe risk: 500 mg IV TDS for 3–5 days
Paediatric dose
50–100 mg IV or PO daily for ≥3 days
Route & frequency
IV preferred in high-risk; once daily, given ≥30 min before nutrition starts
Renal adjustment
Not required — water-soluble vitamin
PBS status
✔ PBS General Benefit
Vitamin B Complex Injection
Pabrinex® IV/IM High Potency
Adult dose
2 pairs of ampoules IV or IM daily for 3 days (provides B1, B2, B3, B6, C)
Paediatric dose
Paediatric formulation or single pair IV/IM daily
Route & frequency
IV infusion over 30 min or IM; once daily
PBS status
✔ PBS General Benefit
Step 2: Caloric Initiation & Titration
The rate of caloric reintroduction must be graded according to risk level:
Highest Risk
BMI <16 or >15% weight loss
Start at 5 kcal/kg/day (max 10 kcal/kg/day on day 1). Titrate by no more than 5 kcal/kg/day every 2–3 days. Goal may take 4–7 days to reach.
Setting: Inpatient, continuous telemetry, HDU if haemodynamically unstable
High Risk
Meets ≥2 other-risk criteria
Start at 10–15 kcal/kg/day. Titrate by 5–10 kcal/kg/day every 2–3 days. Ensure electrolytes normal before each increase.
Setting: Inpatient with daily electrolyte monitoring
Moderate Risk
Single risk factor or borderline
Start at 15 kcal/kg/day. May titrate to goal over 2–3 days. Monitor electrolytes daily for 48 hours.
Setting: Inpatient or supervised outpatient
Key principle: Carbohydrate-rich feeds stimulate the highest insulin response. Consider using feeds with a lower carbohydrate-to-fat ratio (e.g., high-fat enteral feeds or intravenous lipid emulsions) in highest-risk patients. Avoid IV dextrose boluses in the first 48 hours.
Step 3: Electrolyte Replacement Protocol
Prophylactic electrolyte replacement must begin from day 1 of refeeding, regardless of whether serum levels are within normal range. Intracellular depletion is universal in malnourished patients.
Phosphate
Sodium Glycerophosphate (Glycophos®) IV · Phosphate Sandoz® PO
Prophylactic dose
0.3–0.6 mmol/kg/day IV or PO, divided into 2–3 doses
Treatment dose
0.6–1.0 mmol/kg/day IV if phosphate <0.6 mmol/L
Route
IV (Glycophos) preferred initially; PO (Phosphate Sandoz 1–2 tabs TDS) when tolerating oral intake
Renal adjustment
Caution if eGFR <30 mL/min — monitor closely, reduce dose by 50%
PBS status
✔ PBS General Benefit
Magnesium
Magnesium Sulfate IV · Magmin® PO
Prophylactic dose
0.2 mmol/kg/day IV or PO, divided
Treatment dose
0.4–0.8 mmol/kg/day IV if Mg <0.5 mmol/L
Route
IV bolus (max 10 mmol/hr) or PO (Magmin 2–4 tabs TDS)
Renal adjustment
Contraindicated if severe renal impairment without monitoring; reduce dose
PBS status
✔ PBS General Benefit
Potassium
Potassium Chloride (KCl) IV · Span-K® Slow-K® PO
Prophylactic dose
1–2 mmol/kg/day IV or PO, divided
Treatment dose
2–3 mmol/kg/day if K⁺ <3.0 mmol/L; max IV rate 20 mmol/hr via central line
Route
IV via peripheral (max 10 mmol/hr) or central line (max 20 mmol/hr); PO preferred when possible
Renal adjustment
Hold and reassess if oliguric or eGFR <15; monitor closely in CKD
PBS status
✔ PBS General Benefit
Step 4: Fluid Management
Fluid caution: Rehydration must be gradual. High insulin levels cause sodium and water retention. Overly aggressive fluid administration risks acute pulmonary oedema, especially in malnourished patients with reduced myocardial reserve. Restrict total fluid intake to 15–20 mL/kg/day (including nutrition fluids) in the first 48–72 hours. Weigh daily and monitor fluid balance strictly.
Step 5: Cardiac & Clinical Monitoring
| Monitoring Parameter | Frequency | Duration |
|---|---|---|
| Serum phosphate, potassium, magnesium | Every 12 hours (daily minimum) | First 72 hours, then daily until stable for 48 h |
| Serum sodium, calcium, glucose | Daily | First 7 days |
| Urea, creatinine, eGFR | Daily | First 3–5 days |
| 12-lead ECG | Baseline + repeat if K⁺, Mg²⁺ or PO₄³⁻ abnormal | Throughout refeeding |
| Continuous telemetry | Continuous | Highest-risk patients for first 72 hours |
| Fluid balance (strict I&O) | Hourly | First 72 hours, then 4–6 hourly |
| Daily weight | Daily, same time, same scales | Minimum first 7 days |
| Respiratory rate, SpO₂ | 4-hourly minimum | First 5 days |
Step 6: Multidisciplinary Nutrition Support
Refeeding syndrome prevention and management requires a coordinated multidisciplinary approach:
- Dietitian (Accredited Practising): Leads nutritional assessment, prescribes feeding regimen, caloric titration schedule, and electrolyte replacement calculations. Must review daily in highest-risk patients.
- Medical officer / physician: Oversees overall management, interprets electrolytes and ECG, manages acute complications, prescribes IV supplementation.
- Pharmacist: Verifies electrolyte dosing, checks for drug–nutrient interactions (e.g., diuretics, insulin, digoxin), ensures thiamine is given prior to feeds.
- Nursing: Monitors fluid balance, vital signs, administers IV electrolytes, assesses for oedema and respiratory deterioration. Must escalate phosphate <0.5 mmol/L urgently.
- Mental health team: Essential for anorexia nervosa and chronic alcohol use disorder. Psychological support, motivational interviewing, and supervised meal plans improve outcomes.
- Speech pathology: Swallowing assessment where dysphagia may be contributing to malnutrition (e.g., post-stroke, neurological disease).
1
Identify at-risk patients
Use NICE/ASPEN criteria at every nutritional assessment
2
Give thiamine first
200–300 mg IV/PO ≥30 min before nutrition; continue for ≥3 days
3
Start low, go slow
5–10 kcal/kg/day for highest risk; titrate by 5 kcal/kg every 2–3 days
4
Replace electrolytes daily
PO₄, Mg²⁺, K⁺ prophylactically from day 1
5
Monitor relentlessly
Electrolytes 12-hourly × 72 h; ECG; fluid balance; daily weight
6
Titrate carefully
Only increase calories when electrolytes are normal and patient is stable
Special Populations
Paediatrics
RFS risk criteria differ slightly — use NICE CG32 age-adjusted thresholds and ensure weight-based calculations are accurate.
Thiamine: 50–100 mg IV/PO daily × 3 days. Electrolyte replacement: weight-based dosing. Paediatric dietitian should lead caloric initiation at 5–10 kcal/kg/day in malnourished children. Children with cerebral palsy, congenital heart disease and chronic GI conditions are at particular risk.
Pregnancy
Severe hyperemesis gravidarum with prolonged vomiting (>5 days minimal intake) is a high-risk RFS scenario.
Thiamine 200–300 mg IV must be given before any IV dextrose in hyperemesis — this is critical to prevent Wernicke encephalopathy. Electrolyte replacement must account for pregnancy reference ranges (phosphate slightly lower in normal pregnancy). Involve obstetric team early.
Elderly
Malnutrition prevalence in aged care is 22–50%. Reduced cardiac reserve makes RFS fluid overload especially dangerous.
Lower threshold for RFS screening. Polypharmacy may include diuretics (worsening hypokalaemia/hypomagnesaemia), PPIs (hypomagnesaemia) and digoxin (toxicity potentiated by hypokalaemia). Review medications before refeeding. Restrict fluids more conservatively (15 mL/kg/day).
Renal Impairment
CKD patients have impaired electrolyte excretion — risk of hyperkalaemia and hyperphosphataemia if replacement is too aggressive.
Reduce electrolyte replacement doses by 50% if eGFR <30. Monitor electrolytes 6–8 hourly. Involve nephrology for patients on dialysis — refeeding between dialysis sessions requires careful fluid and electrolyte planning.
Hepatic Impairment
Cirrhosis patients are frequently malnourished (up to 90% in decompensated cirrhosis). Hepatic glycogen stores are depleted.
Use low-carbohydrate, high-lipid feeds to reduce insulin surge. Monitor for hepatic encephalopathy — branched-chain amino acid (BCAA)-enriched feeds may be considered. Avoid overfeeding: aim for 20–25 kcal/kg/day long-term target. LFT monitoring important.
Immunocompromised
Chemotherapy-induced mucositis and anorexia place oncology patients at high RFS risk.
Start refeeding cautiously after each chemotherapy cycle. Monitor for neutropenic sepsis compounding metabolic derangement. Consider parenteral nutrition if enteral route not feasible. Thiamine, folate and zinc should be included in supplementation regimen.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. National Institute for Health and Care Excellence (NICE). Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical guideline CG32. London: NICE; 2006 (updated 2017).
- 2. da Silva JSV, Seres DS, Sabino K, et al. ASPEN consensus recommendations for refeeding syndrome. Nutrition in Clinical Practice. 2020;35(2):178–195.
- 3. Friedli N, Stanga Z, Sobotka L, et al. Revisiting the refeeding syndrome: results of a systematic review. Nutrition. 2017;35:151–160.
- 4. Crook MA, Hally V, Panteli JV. The importance of the refeeding syndrome. Nutrition. 2001;17(7–8):632–637.
- 5. Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ. 2008;336(7659):1495–1498.
- 6. Stanga Z, Brunner A, Braga M, et al. Artificial nutrition in clinical practice: refeeding syndrome. Best Practice & Research Clinical Gastroenterology. 2023;64–65:101842.
- 7. Australian Institute of Health and Welfare (AIHW). Nutrition across the life stages. Cat. no. PHE 227. Canberra: AIHW; 2018.
- 8. Australasian Society of Parenteral and Enteral Nutrition (AuSPEN). AuSPEN clinical guidelines for parenteral and enteral nutrition. Asia Pacific Journal of Clinical Nutrition. 2014;23(4):522–540.
- 9. National Health and Medical Research Council (NHMRC). Australian dietary guidelines. Canberra: NHMRC; 2013.
- 10. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 10th edition. East Melbourne: RACGP; 2024.
- 11. World Health Organization (WHO). Guideline: updates on the management of severe acute malnutrition in infants and children. Geneva: WHO; 2013.
- 12. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd edition. Sydney: ACSQHC; 2021.